Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global
medical technology company focused on surgical solutions for the
treatment of spinal disorders, honors Asante Contreras, a donor
hero, as part of its continued sponsorship of the 2023 Donate Life
Float at the Rose Parade in Pasadena on Monday, January 2, 2023.
The 2023 Donate Life Rose Parade float is titled Lifting Each Other
Up.
Asante is remembered for his smile, positive
energy, and dedication to helping others. He hoped to be an
emergency room physician and became an EMT to save money for
medical school. Sadly, he passed a day before taking the test
needed to complete the Paramedic Certification Program at UT Health
San Antonio. The school honored Asante’s work by giving him his
certification posthumously. Asante was able to leave one final,
lasting gift as a cornea and tissue donor.
“Asante’s passion for caring for others shone
through in his final gift, ultimately allowing others to live a
full life,” said Sean Browne, President, and CEO of Xtant Medical.
“We honor his incredible life and legacy by reinforcing the values
and lifesaving opportunities that donation brings to patients in
need. Our support for Asante, Donate Life, and Lifting Each Other
Up further enables Xtant Medical’s mission of ‘honoring the gift of
donation, by allowing our patients to live as full, and complete a
life as possible.’”
Organ, eye, and tissue donation offers hope to
donor families who, in the midst of losing a loved one, see the
chance to believe their loved ones’ gifts will help save others. At
the same time, those waiting to receive a lifesaving organ have the
dream and hope that a donor will become available to restore their
health and change their lives. They can now achieve their life’s
goals, all thanks to their donors. The Donate Life Rose Parade
float is celebrating its 20th year of participating in this
national effort to reach viewers and share the vital message that
organ, eye, and tissue donation saves and heals lives. Xtant
Medical is proud to be part of this noble endeavor.
As the world’s most visible campaign to inspire
organ, eye, and tissue donation, The Donate Life Rose Parade float
inspires viewers to help the over one million people in need of
organ, eye, or tissue transplants each year. Register today to
become an organ, eye, or tissue donor by visiting
www.DonateLife.net.
About Donate Life America
(DLA)
Donate Life America is a 501(c)3 not-for-profit
alliance of national organizations and state teams across the
United States committed to increasing organ, eye, and tissue
donation. Donate Life America manages and promotes the national
brand for donation, Donate Life, and assists Donate Life State
Teams and national partners in facilitating high-performing donor
registries; developing and executing effective multi-media donor
education programs; and motivating the American public to register
now as organ, eye and tissue donors.
About Xtant Medical Holdings,
Inc.
Xtant Medical Holdings, Inc.
(www.xtantmedical.com) is a global medical technology company
focused on the design, development, and commercialization of a
comprehensive portfolio of orthobiologics and spinal implant
systems to facilitate spinal fusion in complex spine, deformity and
degenerative procedures. Xtant people are dedicated and talented,
operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and
registered trademarks of Xtant Medical Holdings, Inc. or its
affiliates, registered as indicated in the United States, and in
other countries. All other trademarks and trade names referred to
in this release are the property of their respective owners.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
that are predictive in nature, that depend upon or refer to future
events or conditions, or that include words such as “intends,”
‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’
‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going
forward,” similar expressions or the negative thereof, and the use
of future dates. Forward-looking statements in this release include
the Company’s expectations to be at full operating capacity by the
first quarter of 2023 and to continue to execute its growth
strategy and deliver on its objectives. The Company cautions that
its forward-looking statements by their nature involve risks and
uncertainties, and actual results may differ materially depending
on a variety of important factors, including, among others: the
Company’s future operating results and financial performance; the
ability to increase or maintain revenue; possible future impairment
charges to long-lived assets and goodwill and write-downs of excess
inventory if revenues continue to decrease; the ability to remain
competitive; the ability to innovate, develop and introduce new
products; the ability to engage and retain new and existing
independent distributors and agents and qualified personnel and the
Company’s dependence on key independent agents for a significant
portion of its revenue; the effect of the COVID-19 pandemic and
labor and staffing shortages on the Company’s business, operating
results and financial condition, especially when they affect key
markets; the Company’s ability to implement successfully its future
growth initiatives and risks associated therewith; the effect of
inflation, increased interest rates and other recessionary
indicators and supply chain disruptions; the effect of product
sales mix changes on the Company’s financial results; government
and third-party coverage and reimbursement for Company products;
the ability to obtain and maintain regulatory approvals and comply
with government regulations; the effect of product liability claims
and other litigation to which the Company may be subject; the
effect of product recalls and defects; the ability to obtain and
protect Company intellectual property and proprietary rights and
operate without infringing the rights of others; the ability to
service Company debt, comply with its debt covenants and access
additional indebtedness; the ability to obtain additional financing
on favorable terms or at all; and other factors. Additional risk
factors are contained in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2021 filed with the Securities and
Exchange Commission (SEC) on March 8, 2022 and subsequent SEC
filings by the Company, including without limitation its most
recent Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022 anticipated to be filed with the SEC. Investors
are encouraged to read the Company’s filings with the SEC,
available at www.sec.gov, for a discussion of these and other risks
and uncertainties. The Company undertakes no obligation to release
publicly any revisions to any forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, except as required by law. All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
this cautionary statement.
Investor Relations Contact
David CareyLazar FINNPh: 212-867-1762Email:
david.carey@finnpartners.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/868ec792-358e-466c-b784-157c5ab4d4ca
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Apr 2023 to Apr 2024